| Literature DB >> 26069452 |
Yukiko Yoshiura1, Hiroto Izumi1, Takako Oyabu2, Masayoshi Hashiba1, Tatsunori Kambara1, Yohei Mizuguchi2, Byeong Woo Lee2, Takami Okada2, Taisuke Tomonaga1, Toshihiko Myojo2, Kazuhiro Yamamoto3, Shinichi Kitajima4, Masanori Horie5, Etsushi Kuroda6, Yasuo Morimoto1.
Abstract
In order to investigate the pulmonary toxicity of titanium dioxide (TiO2) nanoparticles, we performed an intratracheal instillation study with rats of well-dispersed TiO2 nanoparticles and examined the pulmonary inflammation and histopathological changes in the lung. Wistar Hannover rats were intratracheally administered 0.2 mg (0.66 mg/kg) and 1.0 mg (3.3 mg/kg) of well-dispersed TiO2 nanoparticles (P90; diameter of agglomerates: 25 nm), then the pulmonary inflammation responses were examined from 3 days to 6 months after the instillation, and the pathological features were examined up to 24 months. Transient inflammation and the upregulation of chemokines in the broncho-alveolar lavage fluid were observed for 1 month. No respiratory tumors or severe fibrosis were observed during the recovery time. These data suggest that transient inflammation induced by TiO2 may not lead to chronic, irreversible legions in the lung, and that TiO2 nanoparticles may not have a high potential for lung disorder.Entities:
Keywords: Chemokine; Environmental and health effects; Intratracheal instillation; Nanoparticle; Pulmonary inflammation; Titanium dioxide
Year: 2015 PMID: 26069452 PMCID: PMC4451463 DOI: 10.1007/s11051-015-3054-x
Source DB: PubMed Journal: J Nanopart Res ISSN: 1388-0764 Impact factor: 2.253
Fig. 1Low magnification (a) and high magnification (b) TEM images of the TiO2 suspensions used in this study
Fig. 2Analysis of BALF after intratracheal instillation of TiO2 nanoparticles. Number of total cell, neutrophils, and macrophages in BALF were counted. Each column and bar represent the mean ± standard deviation of five rats. Asterisk indicates significant differences compared with each control (ANOVA, Dunnett T3) (*p < 0.05)
Fig. 3Concentration of CINCs in BALF and lung tissue after intratracheal instillation of TiO2 nanoparticles. Concentrations of CINC-1 and CINC-2 in BALF and lung tissue were evaluated with an ELISA kit with specific antibodies. Each column and bar represent the mean ± standard deviation of five rats. Asterisk indicates significant differences compared with each control (ANOVA, Dunnett T3) (**p < 0.01, *p < 0.05)
Fig. 4HO-1 concentration in BALF and lung tissue after intratracheal instillation of TiO2 nanoparticles. Concentrations of HO-1 in BALF and lung tissue were evaluated with an ELISA kit with specific antibodies. Each column and bar represent the mean ± standard deviation of five rats. Asterisk indicates significant differences compared with each control. (ANOVA, Dunnett T3) (**p < 0.01, *p < 0.05)
Fig. 5Histological changes in lungs. 3 days post exposure to TiO2 in the 1.0 mg-administered group (×200) (a) and (×400) (b). 6 months post exposure in the 1.0 mg-administered group (×200) (c) and (×400) (d). Arrow particle-laden macrophages containing brown particles in their enlarged cytoplasm. (Color figure online)
Histological changes in the lung
| Pathological feature | 3 days ( | 1 week ( | 1 month ( | 3 months ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | TiO2 0.2 mg | TiO2 1.0 mg | Control | TiO2
| TiO2
| Control | TiO2
| TiO2
| Control | TiO2
| TiO2
| |
| Macrophage infiltration | ± ~ + | + | + ~ ++ | ± ~ + | + | ++ | ± | ± | + | ± | + | + |
| Infiltration in interstitial area | − ~ ± | − or + | + | − ~ ± | − ~ + | − ~ + | − ~ + | − | − ~ + | ± ~ + | + ~ ++ | ± |
| Fibrosis | − | − | − | − | − | − | − | − | − | − | − | − |
| Benign tumor | − | − | − | − | − | − | − | − | − | − | − | − |
| Malignant tumor | − | − | − | − | − | − | − | − | − | − | − | − |
Grade of changes: − none, ± minimum, + mild, ++ moderate, +++ remarked
Fig. 6TEM images after exposure to TiO2. After 3 days in the 0.2 mg-administered group (a) and the 1.0 mg-administered group (b–d), after 28 days in the 0.2 mg-administered group (e) and the 1.0 mg-administered group (f), after 6 months in the 0.2 mg-administered group (g) and the 1.0 mg-administered group (h), after 12 months in the 1.0 mg-administered group (i). Arrow TiO2 aggregates in the alveolar macrophages, dotted arrow TiO2 aggregates wrapped with alveolar surfactant, arrowhead TiO2 in the alveolar cells